Table. Patient Characteristicsa.
| Characteristic | UCSF Cohort (n = 761) | Post-2005/IDH Known Subset (n = 434) |
|---|---|---|
| Sex | ||
| Male | 468/761 (61.5) | 271/434 (62.4) |
| Female | 293/761 (38.5) | 163/434 (37.6) |
| Age at diagnosis, y | ||
| Mean (SD) | 59.5 (12.0) | 59.6 (11.5) |
| Median (IQR) | 60.0 (51.6-67.7) | 60.5 (52.2-67.4) |
| Range | 19.0-89.0 | 21.3-89.0 |
| Diagnosis year | ||
| Before 2005 | 122/761 (16.0) | 0/434 |
| 2005 and after | 639/761 (84.0) | 434/434 (100) |
| KPSb | ||
| <60 | 35/451 (7.8) | 19/241 (7.9) |
| 60 | 24/451 (5.3) | 10/241 (4.1) |
| 70 | 50/451 (11.1) | 34/241 (14.1) |
| 80 | 149/451 (33.0) | 72/241 (29.9) |
| 90 | 173/451 (38.4) | 92/241 (38.2) |
| 100 | 20/451 (4.4) | 14/241 (5.8) |
| Median KPS (IQR) | 80 (80-90) | 80 (70-90) |
| Tumor location by lobe | ||
| Brainstem, insular, basal ganglia, or thalamus | 14/704 (2.0) | 11/414 (2.7) |
| Cerebellum | 2/704 (0.3) | 1/414 (0.2) |
| Frontal | 268/704 (38.1) | 153/414 (37.0) |
| Occipital | 46/704 (6.5) | 29/414 (7.0) |
| Parietal | 137/704 (19.5) | 74/414 (17.9) |
| Temporal | 237/704 (33.7) | 146/414 (35.3) |
| Tumor location by hemisphere | ||
| Bilateral | 8/705 (1.1) | 4/414 (1.0) |
| Left | 357/705 (50.6) | 205/414 (49.5) |
| Right | 340/705 (48.2) | 205/414 (49.5) |
| IDH status | ||
| Wild type | 478/514 (93.0) | 403/434 (92.9) |
| Mutant | 36/514 (7.0) | 31/434 (7.1) |
| MGMT status | ||
| Methylated | 94/205 (45.9) | 89/197 (45.2) |
| Unmethylated | 111/205 (54.1) | 108/197 (54.8) |
| Postoperative adjuvant therapy | ||
| Postoperative radiotherapy | 677/741 (91.4) | 399/424 (94.1) |
| Postoperative temozolomide | 628/741 (84.8) | 386/424 (91.0) |
| Both | 619/741 (83.5) | 380/424 (89.6) |
| Neither | 64/741 (8.6) | 20/424 (4.7) |
| Preoperative volume, mL | ||
| CE tumors | ||
| Mean (SD) | 32.6 (28.2) | 31.3 (27.9) |
| Median (IQR) | 24.8 (10.7-46.9) | 22.9 (11.0-44.3) |
| Range | 0.1-173.8 | 0.1-172.1 |
| NCE tumors | ||
| Mean (SD) | 85.3 (55.7) | 82.6 (54.7) |
| Median (IQR) | 75.0 (40.3-121.2) | 73.3 (37.7-121.1) |
| Range | 1.2-274.8 | 1.2-266.3 |
| Postoperative volume, mL | ||
| CE tumors | ||
| Mean (SD) | 3.2 (6.9) | 3.1 (7.1) |
| Median (Q1-Q3) | 0.6 (0.0-3.1) | 0.5 (0.0-2.8) |
| Range | 0.0-57.6 | 0.0-57.6 |
| NCE tumors | ||
| Mean (SD) | 40.2 (33.4) | 36.7 (32.6) |
| Median (IQR) | 33.8 (13.5-56.8) | 29.8 (10.8-51.7) |
| Range | 0.0-200.3 | 0.0-200.3 |
| Extent of resection, % by volume | ||
| CE tumors | ||
| Mean (SD) | 89.6 (17.2) | 90.0 (16.9) |
| Median (Q1-Q3) | 97.3 (87.3-100) | 97.5 (88.4-100) |
| Range | 9.9-100.0 | 9.9-100.0 |
| NCE tumors | ||
| Mean (SD) | 53.7 (23.3) | 56.7 (23.3) |
| Median (Q1-Q3) | 54.0 (39.0-70.0) | 58.0 (43.0-73.0) |
| Range | 0.0-100 | 0.0-100 |
Abbreviations: CE, contrast enhanced; IDH, isocitrate dehydrogenase 1 or 2 gene; IQR, interquartile range; KPS, Karnofsky Performance Score; MGMT, promoter region of the DNA repair enzyme O6-methylguanine-DNA methyltransferase; NCE, non–contrast enhanced.
a
Unless otherwise indicated, data were expressed as number/total number (percentage) of patients. Percentages have been rounded and may not total 100.
b
Higher scores indicate a better ability to carry out daily activities.